

Dr. med. PhD Beatrice Davina Barda

PROFESSIONAL CURRICULUM VITAE

Personal data

Date of birth: 17/09/1982

Place of origin: Milan

Nationality: Italian

Email: Beatrice.barda@gmail.com

Preuniversity training

- 1988-1992 Primary school, Location: Milan
- 1993-1995 Secondary school, Location: Milan
- 1996-2001 High school, Location: Milan

University training

- 2001-2002: University of Biotechnology, Vita e Salute San Raffaele, Milan
- 2002-2008: University of Medicine, Vita e Salute San Raffaele, Milan
- 2009-2014: Residency Clinical Microbiology and Virology at Vita e Salute San Raffaele, Milan
- 2014-2017: PhD in Epidemiology at Swiss Tropical and Public Health Institute

Language knowledge

Italian (mother tongue)

English (Advanced. Cambridge CPE: Certificate of Proficiency in English (1999).
Cambridge

CAE: Certificate in Advanced English (1999). Cambridge FCE: First Certificate in
English
(1997)

French: Very good understanding and good speaking and writing

German and Spanish: basic

Postgraduate position

- 2009 -2011 Assistant physician

Division: Infectious diseases ward San Raffaele hospital, Milan (Director Prof Dr Med
Adriano Lazzarin)

- 2011-2014: Resident physician

Division: Microbiology laboratory: San Raffaele hospital, Milan (Director Prof Dr Med
Massimo Clementi)

Studies on HIV mutations and drug resistance

- 2014-2017 PhD in Epidemiology

Division: at Swiss Tropical and Public Health Institute, Basel, Switzerland
 Department of infection biology and drug development (Director Prof Jennifer Keiser)

- 01.01.2018-31.05.2018: Post PhD
 Clinical trials in drug development for intestinal parasitic infections. Swiss Tropical and Public Health Institute, Basel, Switzerland
 Department of infection biology and drug development (Director Prof Jennifer Keiser)
- 01.08.2018-31.12.2019: assistant physician
 Division: Internal medicine and oncology, Hospital: Clinica Luganese, Country Switzerland (Director: Prof Dr Med Andreas Cerny)
- 01-01.2020-31.08.2020: assistant physician and researcher
 Division: Epatocentro Ticino (Director Prof Dr Med Andreas Cerny)
- 01.09.2020-31.08.2022 assistant physician
 Division: Ospedale La Carità Locarno
- 01.09.2022 -31.12.2022 assistant physician (50%)
 Division: Ospedale Civico di Lugano infectious diseases department
- 01.09.2022-31.12.2022 researcher (50%)
 Division: Fondazione Epatocentro Ticino
- 01.01.2023-30.04.2024
 Division of infectious diseases at Hospital Cantonale Regionale (Director Prof Dr Med Enos Bernasconi)
- 01.05.2024- 31.12.2024
 Division of infectious diseases at Centre hospitalier universitaire vaudois (CHUV) (Director Prof Dr Med Daniel Kaufmann)
- 01.11.202 -Up to now
 Division: Fondazione Epatocentro Ticino

Research training

- 2009-2014: Resident physician in: Microbiology laboratory: studies on HIV mutations and drug resistance San Raffaele hospital, Milan (Director Prof Dr Med Massimo Clementi)
- 2014 - December 2017 PhD in Epidemiology; At Swiss Tropical and Public Health Institute,
 Basel, Switzerland - Department of infection biology and drug development (Director Prof Jennifer Keiser)
- 01.01.2018-31.05.2018: Clinical trials in drug development Clinical trials in drug development for intestinal parasitic infections. Swiss Tropical and Public Health Institute, Basel, Switzerland -
 Department of infection biology and drug development (Director Prof Jennifer Keiser)

Certificates

- 1992 Certificate Primary School
- 1995 Certificate Secondary School
- 2001 Certificate High School
- 2008 Certificate Doctor in Medicine
- 2014 Title of speciality Clinical Microbiology and Virology
- 2017 PhD Certificate in Epidemiology
- 2023 FMH Internal general medicine

Counselling for scientific journals - “Reviewer”

The Lancet Infectious diseases
 PloS Neglected Tropical Diseases
 PloOne
 American Journal of Tropical Medicine and Hygiene
 Tropical Medicina & International Health
 Transaction of the Royal Society of Tropical Medicine & Hygiene
 Drug Target Insight: SAGE Journal
 Tropical Biomedicine
 Parasites & Vectors
 Medical Journal of Indonesia
 Journal of Parasitology & Vector Biology

Teaching experience

- 2014 – up to now Teaching parasitology at Master in Tropical Diseases University of Florence, Italy
- 2017 – 2020 Professore a contratto in parasitology and parasitic diseases of animals. LM in Cellular and Molecular Biology. University, Torino
- Presentation at the congress: Pomeriggio di formazione in malattie infettive Gruppo Malattie Infettive Ticino (2018)
- Case-based learning weekly of the Hospital Clinica Luganese (direction: Dr. med Pietro Antonini; 2018-2019)
- Abstract ID 7645 submitted for the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).” Performance of the Seegene Allplex Assay in comparison to microscopy and in-house real-time PCR for the detection of helminths in Tanzanian stool samples.” Rahel Wampfler, Beatrice Barda, Marie-Therese Ruf, Jennifer Keiser
- Oral presentation at the 10th European Congress for Tropical Medicine and International Health in 2017.
- Teach the teacher (USI) February 2022
- Two research projects for Medical Doctor Students 2022
- Presentation at ECCMID 2023: Worm globalization

Scientific production

- **Direction of thesis (MD):** Thesis: Influence of 20 years of HIV infection and treatment on glucose metabolism Italian registration: N 41309. Swiss registration N 7601007560578
- **Direction of thesis (Speciality):** Thesis on: Impact of multiple Mass Drug Administration with DEC and albendazole on intestinal parasites infections in Leogane, Haiti
- **Direction of thesis (PhD):** New drugs, drug combination and improved diagnostics for the control of helminthic infections
- **Principal investigator** of the clinical trial phase 2 on the assessment of efficacy and safety of moxidectin and Synriam® vs praziquantel against *Schistosoma mansoni* and *S. haematobium* infections in adolescents, Côte d'Ivoire Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)
- **Principal investigator** of the clinical trial phase 2 on the assessment of efficacy and safety of moxidectin vs ivermectin against *Strongyloides stercoralis* infection, a community-based trial in Lao People's Democratic Republic
- **Principal investigator** of the clinical trial phase 2 on the assessment of efficacy and safety of moxidectin alone and in combination with albendazole and with tribendimidine vs albendazole/oxantel pamoate against *Trichuris trichiura* infection in adolescents, Pemba Island, Tanzania, Public Health Laboratory, WHO-collaborating centre
- **Principal investigator:** Ultrasound evaluation of *Schistosoma haematobium* related bladder morbidity in infected pre-school and school-aged children before and after treatment with different doses of praziquantel vs placebo, Côte d'Ivoire Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)
- **Principal investigator:** Evaluation and comparison of different diagnostic methods (Baermann method, Kato-Katz, CCA, PCR) for the diagnosis of *Strongyloides stercoralis*, *Schistosoma* spp and Soil transmitted helminth
- **Principal investigator:** Evaluation of a new diagnostic method (Mini-FLOTAC) for the diagnosis of stool parasites in three different low-income settings (India, Tanzania and Argentina).
- **Research funds**
 - 2015: Geigy Foundation For the project trial phase 2 on the assessment of efficacy and safety of moxidectin and Synriam® vs praziquantel against *Schistosoma mansoni* and *S. haematobium* infections in adolescents, Côte d'Ivoire Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)
 - 2017: Bill and Melinda Gates Foundation assessment of efficacy and safety of moxidectin alone and in combination with albendazole and with tribendimidine vs albendazole/oxantel pamoate against *Trichuris trichiura* infection in adolescents, Pemba Island, Tanzania, Public Health Laboratory, WHO-collaborating centre

Fattore di Hirsch (Scopus, verificato il 17.05.2023): 17

Reports published in journals with editorial policy

• Original articles

Canducci F, **Barda B**, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. *Clin Microbiol Infect*. 2011;17(6):928-934. doi: 10.1111/j.1469-0691.2010.03375.x. **Impact factor 2020 8.07, maximum ranking 0.97**

Gianotti N, Visco F, Galli L, **Barda B**, Piatti P, Salpietro S, Bigoloni A, Vinci C, Nozza S, Gallotta G, Lazzarin A, Castagna A. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. *HIV Med*. 2011;12(2):109-117. doi: 10.1111/j.1468-1293.2010.00860.x. **Impact factor 2020 3.18, maximum ranking 0.42**

Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, **Barda B**, Canducci F, Clementi M, Lazzarin A, Castagna A. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. *J Antimicrob Chemother*. 2012;67(1):213-7. doi: 10.1093/jac/dkr422. **Impact factor 2020 5.79, maximum ranking 0.86**

Barda B, Rinaldi L, Ianniello D, Zepherine H, Salvo F, Sadutshang T, Cringoli G, Clementi M, Albonico M. Mini-FLOTAC, an innovative direct diagnostic technique for intestinal parasitic infections: experience from the field. *PLoS Negl Trop Dis*. 2013 ;7(8):e2344. doi: 10.1371/journal.pntd.0002344. **Impact factor 2020 8.07, maximum ranking 0.97**

Barda B, Zepherine H, Rinaldi L, Cringoli G, Burioni R, Clementi M, Albonico M. Mini-FLOTAC and Kato-Katz: helminth eggs watching on the shore of Lake Victoria. *Parasit Vectors*. 2013;6(1):220. doi: 10.1186/1756-3305-6-220. **Impact factor 2020 3.88, maximum ranking 0.91**

Barda B, Cajal P, Villagran E, Cimino R, Juarez M, Krolewiecki A, Rinaldi L, Cringoli G, Burioni R, Albonico M. Mini-FLOTAC, Kato-Katz and McMaster: three methods, one goal; highlights from north Argentina. *Parasit Vectors*. 2014;7:271. doi: 10.1186/1756-3305-7-271. **Impact factor 2020 3.88, maximum ranking 0.91**

Barda B, Ianniello D, Salvo F, Sadutshang T, Rinaldi L, Cringoli G, Burioni R, Albonico M. "Freezing" parasites in pre-Himalayan region, Himachal Pradesh: Experience with

mini-FLOTAC. *Acta Trop.* 2014;130:11-16. doi: 10.1016/j.actatropica.2013.10.008. Impact factor 2020 3.11, maximum ranking 0.87

Barda B, Ianniello D, Zepheryne H, Rinaldi L, Cringoli G, Burioni R, Albonico M. Parasitic infections on the shore of Lake Victoria (East Africa) detected by mini-FLOTAC and standard techniques. *Acta Trop.* 2014;137:140-146. doi: 10.1016/j.actatropica.2014.05.012. Impact factor 2020 3.11, maximum ranking 0.87

Barda B, Albonico M, Ianniello D, Ame SM, Keiser J, Speich B, Rinaldi L, Cringoli G, Burioni R, Montresor A, Utzinger J. How long can stool samples be fixed for an accurate diagnosis of soil-transmitted helminth infection using Mini-FLOTAC? *PLoS Negl Trop Dis.* 2015;9(4):e0003698. doi: 10.1371/journal.pntd.0003698. Impact factor 2020 4.42, maximum ranking 0.96

Albonico M, Becker SL, Odermatt P, Angheben A, Anselmi M, Amor A, **Barda B**, Buonfrate D, Cooper P, Gétaz L, Keiser J, Khieu V, Montresor A, Muñoz J, Requena-Méndez A, Savioli L, Speare R, Steinmann P, van Lieshout L, Utzinger J, Bisoffi Z; StrongNet Working Group. StrongNet: An international network to improve diagnostics and access to treatment for Strongyloidiasis control. *PLoS Negl Trop Dis.* 2016;10(9):e0004898. doi: 10.1371/journal.pntd.0004898. Impact factor 2020 4.42, maximum ranking 0.96

Barda B, Coulibaly JT, Puchkov M, Huwyler J, Hattendorf J, Keiser J. Efficacy and safety of moxidectin, synriam, synriam-praziquantel versus praziquantel against *Schistosoma haematobium* and *S. mansoni* Infections: a randomized, exploratory phase 2 trial. *PLoS Negl Trop Dis.* 2016;10(9):e0005008. doi: 10.1371/journal.pntd.0005008. Impact factor 2020 4.42, maximum ranking 0.96

Barda B, Albonico M, Buonfrate D, Ame SM, Ali S, Speich B, Keiser J. Side benefits of mass drug administration for lymphatic filariasis on *Strongyloides stercoralis* prevalence on Pemba Island, Tanzania. *Am J Trop Med Hyg.* 2017;97(3):681-683. doi: 10.4269/ajtmh.17-0050 (Erratum in: *Am J Trop Med Hyg.* 2018;98(2):635) Impact factor 2020 2.35, maximum ranking 0.57

Barda B, Coulibaly JT, Hatz C, Keiser J. Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with *Schistosoma haematobium* and its evolution after praziquantel treatment: A randomized controlled trial. *PLoS Negl Trop Dis.* 2017;11(2):e0005400. doi: 10.1371/journal.pntd.0005400. Impact factor 2020 4.42, maximum ranking 0.96

Barda B, Sayasone S, Phongluxa K, Xayavong S, Keoduangsy K, Odermatt P, Puchkov M, Huwyler J, Hattendorf J, Keiser J. Efficacy of moxidectin versus ivermectin against

Strongyloides stercoralis infections: a randomized, controlled noninferiority trial. Clin Infect Dis. 2017;65(2):276-281. doi: 10.1093/cid/cix278. Impact factor 2020 9.08, maximum ranking 0.98

Barda B, Ame SM, Ali SM, Albonico M, Puchkov M, Huwyler J, Hattendorf J, Keiser J. Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial. Lancet Infect Dis. 2018;18(8):864-873. Impact factor 2020 25.01, maximum ranking 1.00

Barda B, Wampfler R, Sayasone S, Phongluxa K, Xayavong S, Keoduangsy K, Schindler C, Keiser J. Evaluation of two DNA extraction methods for detection of Strongyloides stercoralis infection. J Clin Microbiol. 2018;56(4):e01941-17. Impact factor 2020 5.95, maximum ranking 0.84

Coulibaly JT, Panic G, Yapi RB, Kovač J, **Barda B**, N'Gbesso YK, Hattendorf J, Keiser J. Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial. BMC Med. 2018;16(1):81. doi: 10.1186/s12916-018-1066-y. Impact factor 2020 8.78, maximum ranking 0.93

Coulibaly JT, Ouattara M, **Barda B**, Utzinger J, N'Goran EK, Keiser J. A rapid appraisal of factors influencing praziquantel treatment compliance in two communities endemic for schistosomiasis in Côte d'Ivoire. Trop Med Infect Dis. 2018;3(2):69. doi: 10.3390/tropicalmed3020069. No Impact Factor

Panic G, **Barda B**, Kovač J, Kovač J, Coulibaly JT, Keiser J. Evaluation of the Clinitek[®], a point-of-care urinalysis system for the measurement of clinically significant urinary metabolites and detection of haematuria in Schistosoma haematobium infected children in southern Côte d'Ivoire. Parasit Vectors. 2019;12(1):298. doi: 10.1186/s13071-019-3555-z. Impact factor 2020 3.88, maximum ranking 0.91

Bongiovanni M, **Barda B** Pseudomonas aeruginosa bloodstream infections in SARS-CoV-2 infected patients: a systematic review. J. Clin. Med. 2023, 12, 2252. <https://doi.org/10.3390/jcm12062252>. Impact factor 2020 4.24, maximum ranking 0.77

• Case reports – letters – Editorials- Narrative reviews

Cauduro A, Favole P, Lorenzo V, Simonetto L, **Barda B**, Cantile C, Asperio RM. Paraparesis caused by vertebral canal leishmaniotic granuloma in a dog. J Vet Intern Med. 2011;25(2):398-9. doi: 10.1111/j.1939-1676.2010.0668.x. Impact factor 2020

3.33, maximum ranking 0.93

Lo Presti G, **Barda B**, Uhr M, Raimondi M, Mora O. Severe dizziness and hypereosinophilia: coincidence or complication? A Case Report. *Case Rep Oncol*. 2020;13(3):1136-1140. doi: 10.1159/000508359. **No Impact Factor**

Barda B, Cerny A. Safety of mRNA-Based Vaccines for SARS CoV-2 *Chem Res Toxicol*. 2021;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. **Impact factor 2020 3.74, maximum ranking 0.60**

Barda B Ivermectin and albendazole against *Trichuris trichiura*: a long and winding road. *Lancet Infect Dis*. 2022;22(1):10-12. doi: 10.1016/S1473-3099(21)00498-9. **Impact factor 2020 25.01, maximum ranking 1.00**

Bongiovanni M, **Barda B**, Martinetti Lucchini G, Invasive listeriosis in Southern Switzerland: a local problem that is actually global. Letter to the author *Clin Inf Dis*. 2023 April; DOI: 10.1093/cid/ciad193. **Impact factor 2020 9.07, maximum ranking 0.97**

Bongiovanni M, **Barda B**, Di Benedetto C, Piccinini D, Bernasconi E
Worm globalization
Acta Trop . 2023 May 9;106941. doi: 10.1016/j.actatropica.2023.106941 **Impact factor 2020 3.11, maximum ranking 0.87**

Piccinini D, Bernasconi E, Carelli M, Luvini G, Di Benedetto C, Lucchini GM, **Barda B**, Bongiovanni M. Parvimonas micra a new potential pathogen in hospitalized patients: a case series from 2015-2022. *Eur J Clin Microbiol Infect Dis*. 2023 May 3. doi: 10.1007/s10096-023-04617-6. **Impact factor: 5.103, maximum ranking: 0.650**

• **Not found in PubMed**

Barda B, Keiser J, Albonico M. Human trichuriasis: diagnostic update. *Curr Trop Med Rep*. 2015;2(4):201–208. doi 10.1007/s40475-015-0063-x. **Not in PubMed**

Barda B Checkpoint for the diagnosis of SARS-CoV-2 infection: a model from Switzerland. *I. J Infect Dis Ther* 2022;10:6. ISSN: 2332-0877 **Not in PubMed**

08.2024

Spide